

Special Issue

Personalized Diagnosis and Treatment of Oligometastatic Disease

Message from the Guest Editor

Recently, several prospective and retrospective studies support the role of radiotherapy, particularly stereotactic body radiotherapy (SBRT), as a safe and effective tool for patients with oligometastatic disease, with proven benefits also in terms of survival, as confirmed by the long-term results of the SABR-COMET trial. To date, SBRT is routinely applied in clinical practice alone or in combination with novel systemic agents, with an increased use of this therapeutic option thanks to the availability of refined diagnostic modalities. The combination of technological progress along with the improved knowledge of biomolecular factors as potential candidates for target therapies, have led clinicians to consider SBRT beyond the consolidated numerical limit of 3–5 metastases and explore other parameters such as the total tumor volume. In this sense, the definition of oligometastatic disease has been reconsidered and recategorized. This Special Issue aims to collect the available evidence and new developments in this complex disease scenario, which is constantly changing shape under the wave of technological and biological advances.

Guest Editor

Dr. Francesco Cuccia
Radiation Oncology Unit, ARNAS Civico Hospital, 90100 Palermo, Italy

Deadline for manuscript submissions

closed (15 September 2025)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/189837

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/journal/

jpm



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on “omics”-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 25 days after submission; acceptance to publication is undertaken in 5.8 days (median values for papers published in this journal in the second half of 2025).